Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
6,116 total articles
Lumentum's optics business is moving from quiet growth to visible AI-infrastructure demand. Recent news - including an Nvidia-backed investment and upcoming S&P 500 inclusion - should tighten supply/demand in the near term. The stock is richly valued on history, but the trade offers a defined risk-reward if you buy the narrative and the catalysts p…
Novo Nordisk is priced like a company that has lost its core franchise. The market reaction has created a high-conviction, asymmetric trade: buy Novo at current levels to capture upside from renewed distribution (Hims & Hers), product life-cycle catalysts and a recovery in investor sentiment. Entry at $38.40, stop $35.00, target $60.00, horizon: lo…
Broadcom is morphing from a diversified semiconductor and software supplier into a high-cash-flow AI infrastructure powerhouse. With custom AI ASICs and next-gen optical DSPs ramping, free cash flow of roughly $26.9B and a fortress balance sheet, the stock merits a long trade with a $400 target and a $295 stop. Valuation is rich, but execution and …
Unusual Machines (UMAC) is transitioning from growth story to execution. After doubling 2025 revenue to $11.2M and signalling positive operating cash flow by year-end 2026, the company has the balance sheet and exposure to domestic defense demand to scale. We upgrade to Buy and lay out a disciplined entry at $20.00, stop at $16.50 and a $35.00 targ…
Henry Schein ($HSIC) looks attractively priced relative to cash flow and peers in medical distribution. The company's $200M efficiency plan, steady free cash flow ($573M), and expanding partnerships provide upside. However, recent margin softness in dental operations, litigation headlines, and mixed technicals argue for a controlled entry, defined …
Pixelworks is a microcap semiconductor play trading near $6 with a thin float and a recently reported cash improvement tied to Shanghai activity. Given low valuation multiples (EV/Sales ~0.76) and an existing royalty/licensing pathway, a disciplined long with a $5.90 entry, $10.00 target and $4.50 stop can capture upside if management converts the …
Netskope (NTSK) is trading near its 52-week low despite 33% sales growth and a reported 118% net retention rate. With a market cap near $3.69B, improving cash dynamics that management highlights as moving to free-cash-flow positive, and technicals showing a decent base, this is a tactical mid-term long: enter at $9.40, stop at $8.50, target $15.00 …
Nvidia's reported $2 billion deal with Nebius is a leverage point for sustained data-center demand, software monetization and higher-margin recurring revenue. The market's cool reaction leaves a tactical opportunity: a mid-term swing trade to capture re-rating if Nebius scales and Nvidia converts the deal into hardware + software attach. Entry, sto…
AeroVironment disappointed with a Q3 miss and negative cash flow, but bookings and counter-drone demand are accelerating. For traders willing to accept execution risk, a mid-term swing long on a pullback offers asymmetric upside while preserving defined risk.
ServiceNow remains the enterprise backbone for workflow automation. Recent AI integrations such as Now Assist and partnerships that harden agent resilience make it more likely customers expand rather than abandon the platform. Given strong subscription growth, $4.6B in free cash flow and low net leverage, I recommend a long trade with a 180-trading…
Eaton is delivering resilient operating performance driven by Electrical and Aerospace segments, supported by a surge in data-center orders. The shares trade at a premium (P/E ~34, market cap ~$137B) but still offer a constructive risk/reward for a disciplined mid-term long trade. Entry at $354.61 with a $338 stop and $381 target balances upside fr…
Bread Financial is trading at single-digit earnings multiples, showing early signs of credit stabilization and modest loan growth. With a market cap around $3.1B, a P/B near 1x and an improving loss picture, the risk/reward looks asymmetric for a tactical long. This trade idea lays out entry, stops, targets and the scenarios that would invalidate t…
Fulgent Genetics (FLGT) trades near cycle lows at ~$14.19 despite a technology-led testing platform, a clean balance sheet, and valuation multiples that look cheap relative to recovery scenarios. The market has punished the stock for legal inquiries and margin volatility; that reaction appears overdone. This trade idea lays out a mid-term long with…
Amazon looks misunderstood by the market. Between structurally higher-margin AWS, accelerating advertising, and expanding AI monetization vectors, the stock offers an asymmetric risk-reward for a mid-term swing. I outline an actionable trade with entry, stop and target, catalysts to watch and what would change my view.
FUTU offers asymmetric upside into 2026 thanks to improving client activity, higher-margin wealth-management revenue, and scalable product-led growth. This trade idea lays out a concrete entry, stop and target with a 180-trading-day horizon and clear catalysts to watch.
Sea Limited (SE) has been punished recently despite beating Q4 revenue and EPS expectations; the shares trade near their 52-week low at a market cap of roughly $52B, with technicals deeply oversold and a still-positive earnings base. We outline a long trade with entry, stop and target that assumes the market re-rates Sea as growth normalizes and ma…
Red Violet (RDVT) is a small-cap analytics and identity verification software provider that has been converting product traction into improving free cash flow and rising institutional interest. With a market cap near $610M, a positive MACD histogram, and tangible customer wins in the real estate vertical, this is a mid-term (45 trading days) trade …
Ezcorp (EZPW) offers a play on a re-accelerating pawn-loan cycle. Recent acquisitive growth (1,488 stores after the Founders One deal), healthy free cash flow ($122m) and an EV/EBITDA of 8.7 argue for a tactical long. This trade targets $32 with a $23 stop; horizon: long term (180 trading days).
AeroVironment pulled back after a conservative Q3 print and guidance reset, but its $2.1B backlog, leadership in tactical drones and counter-UAS, improving order cadence, and an attractive technical setup argue for a mid-term long trade. We outline an actionable entry, stop and target with clear risk controls.
Green Brick Partners combines attractive profitability with a conservative balance sheet and an underappreciated growth runway. At $65.58 the stock trades at roughly 8-9x trailing earnings and 1.6x book with EV/EBITDA near 6.8. We upgrade to Strong Buy and lay out an actionable trade plan for a long-term horizon centered on balance-sheet resilience…
LiveRamp is positioning agentic AI on top of its identity and data-collaboration platform to automate audience activation and measurement across channels. Fundamentals show positive free cash flow ($169.3M) and no net debt, while technicals and short interest suggest conviction and potential squeezes. This trade idea takes a constructive stance: en…
Whirlpool (WHR) has been hammered by tariff pain, a dilutive capital raise and a cooling housing cycle. Those headwinds look to be peaking: the company sits at single-digit P/E-like valuation, yields well above 6%, and technicals are deeply oversold. This trade idea proposes a mid-term swing long with a disciplined stop and clear targets while ackn…
Huntington Ingalls (HII) looks like a pragmatic way to play a renewed White House push for a larger U.S. fleet and steady DoD funding for autonomy and ship modernization. The business prints strong free cash flow, trades at a mid-20s PE, and sits near technical support. I recommend a mid-term (45 trading days) tactical long with a defined entry, st…
Eli Lilly remains the central beneficiary of the GLP-1 weight-loss boom. With orforglipron poised to expand oral market share, industry-leading margins, and near-$1 trillion market cap backing continuing cash generation, this is a structured long trade. Valuation is rich, so position sizing and a disciplined stop matter.
Lam Research is positioned to benefit from a multi-year wave of wafer fabrication equipment (WFE) spending driven by AI-capex and memory restocking. Recent beat-and-raise results, strong free cash flow and healthy balance-sheet metrics support a long bias. Valuation is rich today, but the supply-constrained nature of the cycle and durable margins g…
